RGNX (Regenxbio) Margin of Safety % (DCF Dividends Based) : N/A (As of Mar. 16, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Regenxbio's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Regenxbio's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Regenxbio's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Regenxbio's Margin of Safety % (DCF Dividends Based) falls into.

Regenxbio Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Regenxbio's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenxbio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

RB0:Germany

Address

9804 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.regenxbio.com

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Executives

Argeris N Karabelas	director
Curran Simpson	officer: SVP of Technical Operations	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth T. Mills	director, officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Steve Pakola	officer: Chief Medical Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista	officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Allan M. Fox	director, 10 percent owner	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas	officer: Senior VP, General Counsel	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos	officer: Chief Scientific Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo	officer: Chief Medical Officer	C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850